We are a team of highly seasoned drug discoverers, drug developers, and related roles. Leaders join us from the world’s major pharma companies while they are at the top of their game, with direct accountability for scientific delivery and strategy. By joining us, leaders can continue to excel and grow at the front line of science, therapeutics R&D, and strategy. We apply the same principles to our non-R&D roles and support functions.

Our portfolio-model is built around a centralized management team of capital allocators and functional leaders with deep expertise in biology, chemistry and pharmaceutical R&D, manufacturing, commercial strategy, fund-raising and finance, and business development, leveraged over a diverse portfolio of therapeutic programs, each led by a dedicated and seasoned global program leader.

Our team is based in the UK and the USA and comprises many nationalities from all over the world.

Team Apollo photo with whole company on a stage with screens showing the logo either side


Filter by team:

Dr Sanjay Aggarwal is Apollo Therapeutics’ Chief Medical officer. Sanjay has spent over 20 years in the biopharmaceutical industry, including extensive experience in building and leading clinical development teams. He has a track record of taking drugs through development to successful regulatory approvals. He joined Apollo from Angiocrine Bioscience, a clinical stage cell and gene therapy company. Previously he was the architect of the Rezurock™ (belumosudil) development program at Kadmon, leading to its FDA approval for chronic graft versus host disease. Before Kadmon he was the global development lead for Kyprolis® (carfilzomib) at Amgen, leading to its approval in multiple myeloma in the USA, EU and numerous other territories. Earlier in his career, he held positions of increasing responsibility in both biotech (Exelixis, Onyx Pharmaceuticals) and pharma (GSK, Novartis, Sanofi), overseeing development of early and late-stage assets across several therapeutic areas, and including roles in the USA, Europe and Asia-Pacific. Sanjay studied mathematics and medicine to earn his medical degree (MB BChir) from The University of Cambridge where he was a member of Queens’ College. He has an MBA from The University of Chicago Booth School of Business. Clinically, he trained in internal medicine and public health and is a member of the Royal College of Physicians (UK). 

Sue is a highly experienced Executive Assistant who has worked at Board level in various multi-national companies over the past 24 years.  Prior to joining Apollo,  Sue spent twelve  years as Executive Assistant to the Chief Financial Officer & Non Executive Board, and Office Manager at the specialist healthcare company BTG plc.


Malcolm holds a degree and PhD in Pharmacology, and following academic posts with the National Institutes of Health (USA), and National Institute of Medical Research (UK) joined GSK in 2005. While at GSK Malcolm predominantly worked in Respiratory medicine, leading a number of projects from Target ID through Ph2 Proof of Concept. 

Vasundhara Bhargava is a Vice President at Patient Square Capital. Ms. Bhargava has over eight years of investment and acquisition experience, most recently as a vice president at Golden Gate Capital. Earlier in her career, Ms. Bhargava was a private equity investor at GIC, and prior to that was an associate at TPG Capital, the private equity platform of alternative asset manager TPG. Prior to TPG, Ms. Bhargava was an analyst in the investment banking division at Goldman Sachs.

Ms. Bhargava holds a bachelor’s degree in finance, a bachelor’s degree in economics, and a bachelor’s degree in mathematics from Indiana University. She also holds a master’s degree in business administration from Stanford’s Graduate School of Business.

Gemma joined Apollo as an FP&A Business Partner in 2021. She is a Chartered Accountant with over ten years post qualified experience in both Financial Planning and Analysis and Management Accounting roles. She spent four years in Audit at Ernst & Young LLP where she completed her accounting qualifications. 

Richard has with over 24 years of experience in the biotech and pharma industry. He has led projects in both drug discovery and clinical development. Prior to joining Apollo, he has worked at PsiOxus Therapeutics, Amgen and UCB. He obtained a BSc in Biochemistry from the University of Bath, and a PhD from the Institute of Cancer Research. 

Dr Richard Butt is Apollo Therapeutics’ Chief Scientific Officer. He joined Apollo in 2016 and served as the organization’s Chief Executive Officer until 2021. Richard spent more than 20 years at Pfizer, holding multiple leadership roles in preclinical and clinical R&D. During his tenure, he led programs to candidate selection, developed IND-enabling and preclinical regulatory packages, and led design, planning, execution and delivery for over 30 clinical studies spanning Phase 0 to Phase 2. Richard has always focused on project and portfolio leadership across the preclinical, translational and clinical phases of R&D. Richard is a cell biologist with a degree in biochemistry from the University of York and a doctorate from University College London. 

Matthew supports Apollo clinical development programs across the portfolio, applying his experience in rare diseases, haematology, immunology and dermatology from similar positions at Pfizer, Novartis,  and more recently in R&D strategy and consulting.  He holds a BS/ME in Biomedical Engineering from Worcester Polytechnic Institute. 

Megan joined Apollo in 2024 as an In-house Clinical Research Associate, working within clinical operations to support oncology and immunology programs. She has over five years of clinical research experience, including coordinating therapeutic oncology trials at an investigational site and supporting rheumatology trial operations at a biotech startup. With a passion for improving patient care, Megan is committed to ensuring ethical trial practices and compliance.   

Joana has a MSc and PhD in Biotechnology with 15 years of industry experience in antibody discovery and in vitro pharmacology. With a track record in driving the progress of innovative drug discovery programs towards the clinic, Joana has held R&D roles in leading pharma and biotech companies including Genzyme/Sanofi, F-star and Kymab/Sanofi and is a named inventor in several patents and authored high-profile peer-reviewed publications. 

Darren is an expert pharmacologist who leads small molecule drug discovery programs from the early discovery stage through to the clinic. Before joining Apollo as one of the founding scientists, Darren gained 18 years of industry experience at Pfizer and prior to that he obtained a PhD in Molecular Biology from the University of Leeds.

Constantine Chinoporos is senior biopharma executive with an exceptional record of success in sourcing, leading, and closing major transactions that have generated significant shareholder value within both large pharma and small biotech organizations. He has proven to be effective on both the buy and sell sides and is respected as a trusted thought partner to CEOs, with a talent for building strong, productive relationships within the C-suite and with board members.

Constantine Chinoporos joined Applied Therapeutics in December 2023, where he serves as Chief Operating Officer & Chief Business Officer.  Applied Therapeutics is a company focused on addressing unmet medical needs across various therapeutic areas, utilizing a portfolio of next generation aldose reductase inhibitors.  Its lead program, Govorestat (AT-007) for the treatment of galactosemia, a rare inborn error of metabolism, is currently under FDA and EMA review for marketing approval.

Prior to joining Applied, Constantine served as Chief Business Officer and member of the executive leadership team at Albireo Pharmaceuticals, a rare disease company focused on treatment of liver diseases, Constantine quarterbacked the sale of the company to Ipsen Pharmaceuticals, generating a $952M cash buyout plus a $10/share contingent value right (CVR). He spearheaded the out-licensing for both A3907 and A2342 (novel bile acid transport inhibitors), resulting in a considerable global licensing proposal from Ipsen for A3907. He also guided efforts to identify external programs for license/acquisition by Albireo to strengthen their pediatric liver presence.

Prior to joining Albireo, Constantine was a member of the executive leadership team at Boston Pharmaceuticals, a clinical-stage biopharmaceutical company, where he executed 21 product license deals across multiple therapeutic areas, generating the entire company pipeline, with multiple assets still under active development. He oversaw business development (BD) and new product planning, recruited the BD team, and organized BD processes, generating an average of five in-license transactions annually. He also formulated the organization’s therapeutic licensing strategy for oncology and immunology and led out-licensing efforts for the RETi oncology program, which resulted in three term sheets.

Previously at Sanofi S.A., a French multinational pharmaceutical and healthcare company, Constantine headed up the Worldwide Licensing function, as well as the North American and European regional business development teams. He designed and led multiple transactions, including a $2.5B immuno-oncology pact with Regeneron, which included reacquiring rights to the PD1 program (Libtayo) as well as the acquisition of global OTC rights to Cialis from Eli Lilly. He led a global workstream initiative to restructure business development, giving birth to a new organization with 150 FTEs spanning all BD activities as well as R&D Search and Evaluation.

Earlier in his career, Constantine held a series of progressive leadership positions at Genzyme Corporation, where he sold three operating units and conceived and led Project Whitespace, a focused project to identify and acquire external rare disease assets.

Constantine holds an MBA from the Johnson Graduate School of Management at Cornell University and a BA in History also from Cornell University. He is a board member and chair of the Compensation Committee at Elektrofi and a member of the Strategic Advisory Group at Apollo Therapeutics.